Skip to main content
Top
Published in: Cancer Cell International 1/2018

Open Access 01-12-2018 | Primary research

miR-144/451 cluster plays an oncogenic role in esophageal cancer by inhibiting cell invasion

Authors: Zhikui Gao, Peng Zhang, Ming Xie, Han Gao, Lihong Yin, Ran Liu

Published in: Cancer Cell International | Issue 1/2018

Login to get access

Abstract

Background

miRNA clusters are widely expressed across species, accumulating evidence has illustrated that miRNA cluster functioned more efficiently than single miRNA in cancer oncogenesis. It is likely that miRNA clusters are more stable and reliable than individual miRNA to be biomarkers for diagnosis and therapy. We previously found low expression of miR-144/451 was closely related with the risk for esophageal cancer. Researches on miR-144/451 cluster were mostly focused on individual miRNA but not the whole cluster, the regulatory mechanism of miRNA cluster were largely unknown.

Methods

In present study, we firstly analysed biological functions of individual miRNAs of miR-144/451 in ECa9706 transfected with miRNA mimics. We further analysed the biological function of the whole cluster in stable transgenic cell overexpressing miR-144/451. We then performed genome-wide mRNA microarray to detect differentially expressed gene profiles in stable transgenic cells.

Results

Overexpression of miR-144-3p promoted early apoptosis of ECa9706 and inhibited cell migration, cell invasion and cell proliferation. miR-144-5p and miR-451a inhibited cell proliferation, at the same time, miR-451a inhibited cell migration. Overexpression of miR-144/451 leads to the arrest cell cycle from S to G2 and G2 to M,while the invasion ability was obviously inhibited. We further observed c-Myc, p-ERK were downregulated in cells overexpressing miR-144/451, while p53 was up-regulated. The downstream effectors of c-Myc, MMP9 and p-cdc2 were downregulated in miR-144/451 stable transgenic cell. miR-144/451 may or partly inhibited cell cycles and invasion of ECa9706 through inhibiting ERK/c-Myc signaling pathway.

Conclusion

Collectively, we analysed the function of miR-144/451 cluster from individual to overall level. miR-144/451 cluster played proto oncogene role in esophageal cancer by inhibiting cell invasion.
Appendix
Available only for authorised users
Literature
1.
go back to reference McGuire S. World cancer report 2014. Geneva: World Health Organization, International Agency for Research on Cancer, WHO Press; 2015. McGuire S. World cancer report 2014. Geneva: World Health Organization, International Agency for Research on Cancer, WHO Press; 2015.
2.
go back to reference Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRef
3.
go back to reference Hammad H, Kaltenbach T, Soetikno R. Endoscopic submucosal dissection for malignant esophageal lesions. Curr Gastroenterol Rep. 2014;16(5):386.CrossRef Hammad H, Kaltenbach T, Soetikno R. Endoscopic submucosal dissection for malignant esophageal lesions. Curr Gastroenterol Rep. 2014;16(5):386.CrossRef
4.
go back to reference Ikebe M, et al. Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management. Gen Thorac Cardiovasc Surg. 2016;64(7):386–94.CrossRef Ikebe M, et al. Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management. Gen Thorac Cardiovasc Surg. 2016;64(7):386–94.CrossRef
5.
go back to reference Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.CrossRef Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.CrossRef
6.
go back to reference Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5.CrossRef Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5.CrossRef
7.
go back to reference Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.CrossRef Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.CrossRef
8.
go back to reference Yu J, et al. Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun. 2006;349(1):59–68.CrossRef Yu J, et al. Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun. 2006;349(1):59–68.CrossRef
9.
go back to reference Wystub K, et al. miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. PLoS Genetics. 2013;9(9):e1003793.CrossRef Wystub K, et al. miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. PLoS Genetics. 2013;9(9):e1003793.CrossRef
10.
go back to reference Gao Z, et al. Possible tumor suppressive role of the miR-144/451 cluster in esophageal carcinoma as determined by principal component regression analysis. Mol Med Rep. 2016;14(4):3805–13.CrossRef Gao Z, et al. Possible tumor suppressive role of the miR-144/451 cluster in esophageal carcinoma as determined by principal component regression analysis. Mol Med Rep. 2016;14(4):3805–13.CrossRef
11.
go back to reference Zha W, et al. Roles of mir-144-ZFX pathway in growth regulation of non-small-cell lung cancer. PLoS ONE. 2013;8(9):e74175.CrossRef Zha W, et al. Roles of mir-144-ZFX pathway in growth regulation of non-small-cell lung cancer. PLoS ONE. 2013;8(9):e74175.CrossRef
12.
go back to reference Liu J, et al. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res. 2015;34:9.CrossRef Liu J, et al. MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression. J Exp Clin Cancer Res. 2015;34:9.CrossRef
13.
go back to reference Xiao R, Li C, Chai B. miRNA-144 suppresses proliferation and migration of colorectal cancer cells through GSPT1. Biomed Pharmacother. 2015;74:138–44.CrossRef Xiao R, Li C, Chai B. miRNA-144 suppresses proliferation and migration of colorectal cancer cells through GSPT1. Biomed Pharmacother. 2015;74:138–44.CrossRef
14.
go back to reference Ma Y, et al. MicroRNA-144 suppresses tumorigenesis of hepatocellular carcinoma by targeting AKT3. Mol Med Rep. 2015;11(2):1378–83.CrossRef Ma Y, et al. MicroRNA-144 suppresses tumorigenesis of hepatocellular carcinoma by targeting AKT3. Mol Med Rep. 2015;11(2):1378–83.CrossRef
15.
go back to reference Matsushita R, et al. Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer. Br J Cancer. 2015;113(2):282–9.CrossRef Matsushita R, et al. Tumour-suppressive microRNA-144-5p directly targets CCNE1/2 as potential prognostic markers in bladder cancer. Br J Cancer. 2015;113(2):282–9.CrossRef
16.
go back to reference Turczynska KM, et al. Stretch-sensitive down-regulation of the mir-144/451 cluster in vascular smooth muscle and its role in AMP-activated protein kinase signaling. PLoS ONE. 2013;8(5):e65135.CrossRef Turczynska KM, et al. Stretch-sensitive down-regulation of the mir-144/451 cluster in vascular smooth muscle and its role in AMP-activated protein kinase signaling. PLoS ONE. 2013;8(5):e65135.CrossRef
17.
go back to reference Wang R, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011;30(23):2644–58.CrossRef Wang R, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene. 2011;30(23):2644–58.CrossRef
18.
go back to reference Babapoor S, et al. A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion. PLoS ONE. 2014;9(9):e107502.CrossRef Babapoor S, et al. A novel miR-451a isomiR, associated with amelanotypic phenotype, acts as a tumor suppressor in melanoma by retarding cell migration and invasion. PLoS ONE. 2014;9(9):e107502.CrossRef
19.
go back to reference Liu ZR, et al. miR-451a inhibited cell proliferation and enhanced tamoxifen sensitive in breast cancer via macrophage migration inhibitory factor. Biomed Res Int. 2015;2015:12. Liu ZR, et al. miR-451a inhibited cell proliferation and enhanced tamoxifen sensitive in breast cancer via macrophage migration inhibitory factor. Biomed Res Int. 2015;2015:12.
20.
go back to reference Li H-P, et al. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-beta. Carcinogenesis. 2013;34(11):2443–51.CrossRef Li H-P, et al. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-beta. Carcinogenesis. 2013;34(11):2443–51.CrossRef
21.
go back to reference Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3 zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene. 2012;31(1):39–47.CrossRef Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3 zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene. 2012;31(1):39–47.CrossRef
22.
go back to reference Yuan J, et al. The expression and function of miRNA-451 in osteosarcoma. Med Oncol. 2015;32(1):324.CrossRef Yuan J, et al. The expression and function of miRNA-451 in osteosarcoma. Med Oncol. 2015;32(1):324.CrossRef
23.
go back to reference Lee Y, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–60.CrossRef Lee Y, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–60.CrossRef
24.
go back to reference Angbohang A, et al. Downregulation of the canonical WNT signaling pathway by TGF beta 1 inhibits photoreceptor differentiation of adult human Muller glia with stem cell characteristics. Stem Cells Dev. 2016;25(1):1–12.CrossRef Angbohang A, et al. Downregulation of the canonical WNT signaling pathway by TGF beta 1 inhibits photoreceptor differentiation of adult human Muller glia with stem cell characteristics. Stem Cells Dev. 2016;25(1):1–12.CrossRef
25.
go back to reference Hamada F. Wnt signaling and cancer. Kaibogaku zasshi J Anat. 2009;84(4):111–2. Hamada F. Wnt signaling and cancer. Kaibogaku zasshi J Anat. 2009;84(4):111–2.
26.
go back to reference Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–80.CrossRef Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–80.CrossRef
27.
go back to reference Kikuchi A, Kishida S, Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med. 2006;38(1):1–10.CrossRef Kikuchi A, Kishida S, Yamamoto H. Regulation of Wnt signaling by protein-protein interaction and post-translational modifications. Exp Mol Med. 2006;38(1):1–10.CrossRef
28.
go back to reference Liu CM, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108(6):837–47.CrossRef Liu CM, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108(6):837–47.CrossRef
29.
go back to reference Provost E, et al. Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites. J Biol Chem. 2003;278(34):31781–9.CrossRef Provost E, et al. Functional correlates of mutations in beta-catenin exon 3 phosphorylation sites. J Biol Chem. 2003;278(34):31781–9.CrossRef
30.
go back to reference Xu JH, et al. Catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol Carcinog. 2016;55(5):431–9.CrossRef Xu JH, et al. Catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol Carcinog. 2016;55(5):431–9.CrossRef
31.
go back to reference Ponzielli R, et al. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer. 2005;41(16):2485–501.CrossRef Ponzielli R, et al. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer. 2005;41(16):2485–501.CrossRef
32.
go back to reference Oster SK, et al. The myc oncogene: MarvelouslY Complex. Adv Cancer Res. 2002;84:81–154.CrossRef Oster SK, et al. The myc oncogene: MarvelouslY Complex. Adv Cancer Res. 2002;84:81–154.CrossRef
33.
go back to reference Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003;22(56):9007–21.CrossRef Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003;22(56):9007–21.CrossRef
34.
go back to reference Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109(3):321–34.CrossRef Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109(3):321–34.CrossRef
35.
go back to reference Wang W, et al. SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62. Oncogene. 2016;35(4):491–500.CrossRef Wang W, et al. SCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62. Oncogene. 2016;35(4):491–500.CrossRef
36.
go back to reference Yang C-Q, et al. MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells. Cell Physiol Biochem. 2014;34(2):266–76.CrossRef Yang C-Q, et al. MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells. Cell Physiol Biochem. 2014;34(2):266–76.CrossRef
37.
go back to reference Chang MC, et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J. 2012;442:293–302.CrossRef Chang MC, et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J. 2012;442:293–302.CrossRef
38.
go back to reference Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res. 2012;32(4):190–5.CrossRef Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res. 2012;32(4):190–5.CrossRef
39.
go back to reference Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005;7(8):831-U93.CrossRef Aleem E, Kiyokawa H, Kaldis P. Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol. 2005;7(8):831-U93.CrossRef
40.
go back to reference Sun W-J, et al. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol. 2017;127:90–100.CrossRef Sun W-J, et al. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol. 2017;127:90–100.CrossRef
41.
go back to reference Zheng TS, et al. Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc Natl Acad Sci USA. 1998;95(23):13618–23.CrossRef Zheng TS, et al. Caspase-3 controls both cytoplasmic and nuclear events associated with Fas-mediated apoptosis in vivo. Proc Natl Acad Sci USA. 1998;95(23):13618–23.CrossRef
42.
go back to reference Olie RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Can Res. 2000;60(11):2805–9. Olie RA, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Can Res. 2000;60(11):2805–9.
Metadata
Title
miR-144/451 cluster plays an oncogenic role in esophageal cancer by inhibiting cell invasion
Authors
Zhikui Gao
Peng Zhang
Ming Xie
Han Gao
Lihong Yin
Ran Liu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-018-0679-8

Other articles of this Issue 1/2018

Cancer Cell International 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine